ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Aarti Drugs reports Q1 FY27 revenue of ₹704 Cr, up 19% YoY. Management focuses on scaling regulated market sales through high-margin formulations and oncology backward integration.
Aarti Drugs reported Q1 FY27 revenue of ₹703.6 Cr, up 19% YoY, with EBITDA rising 30% to ₹96.9 Cr. Strategy focuses on backward integration at Sayakha and USFDA-regulated market expansion.
Aarti Drugs reported Q1FY27 revenue of ₹703.6 Cr with 19% YoY growth. EBITDA rose 30% to ₹96.9 Cr, driven by volume growth and improved pricing realizations across API and Specialty Chemicals portfolios.
Aarti Drugs reported Q4 FY26 revenue of ₹721.1 Cr (up 6% YoY) with EBITDA margins at 13.4%. Management is transitioning from investment to an operational scale-up phase despite geopolitical headwinds.
Aarti Drugs reported FY26 revenue of ₹2,568 Cr (+7% YoY) and PAT of ₹195 Cr (+16% YoY). Q4 saw strong sequential recovery with 20% revenue growth, driven by Sayakha facility scale-up.
Aarti Drugs reported FY26 revenue of ₹2,568 Cr (+7% YoY) and PAT of ₹195 Cr (+16% YoY), driven by the Sayakha facility scale-up and improved export traction despite pricing pressures.